SF3087 (Legislative Session 94 (2025-2026))
Restrictions placed on the sale of certain over-the-counter allergy medications modifications
Related bill: HF2476
AI Generated Summary
Purpose of the Bill
The bill aims to modify the restrictions surrounding the sale of certain over-the-counter allergy medications that contain methamphetamine precursor drugs like ephedrine or pseudoephedrine. These changes are primarily intended to prevent the misuse of these drugs for methamphetamine production.
Main Provisions
- Schedule V Drugs: The bill lists specific quantities of narcotic drugs and non-narcotic ingredients, including ephedrine and pseudoephedrine, under Schedule V restrictions to control their distribution and prevent unlawful use.
- Sales Limitations: The bill restricts single over-the-counter transactions to a maximum of three packages or six grams of methamphetamine precursor drugs, such as those containing ephedrine or pseudoephedrine.
- Purchase and Identification Requirements: Retailers must store these drugs behind the counter and sell them only with the assistance of a licensed pharmacist, registered pharmacy technician, or pharmacy clerk. Buyers must present a photo ID and sign a documentation form recording the sale details, which is kept for three years for potential law enforcement review.
- 30-Day Purchase Limit: Individuals are limited to purchasing no more than 7.2 grams of methamphetamine precursor drugs within a 30-day period.
- Underage Sales Prohibition: Sales of methamphetamine precursor drugs are prohibited to anyone under 18 years of age.
- Penalties: Violators, including businesses and individuals who fail to comply with these regulations, could face misdemeanor charges, which include fines up to $1,000 and imprisonment for up to 90 days.
- Exemptions and Preemptions: The bill exempts pediatric products, certain gel or liquid forms, and specific manufacturing processes from these restrictions. It also preempts local laws by establishing a unified statewide regulation.
Significant Changes
- Increased Purchase Limits: The bill increases the single sale limit to three packages or six grams per transaction, while maintaining the 30-day purchase limit at 7.2 grams, accommodating for varying dosage forms.
- Business Compliance and Liability: It outlines clear requirements for business establishments to prevent unauthorized sales and offers immunity from civil liability for reporting suspicious transactions in good faith.
- Preemption of Local Laws: All local ordinances enacted before the bill’s effective date dealing with the sale of these drugs are void, creating a consistent statewide policy.
Relevant Terms
- Methamphetamine precursor drugs
- Ephedrine
- Pseudoephedrine
- Over-the-counter sale
- Schedule V restrictions
- Photo identification
- Misdemeanor charges
- Statewide regulation
Bill text versions
- Introduction PDF file
Actions
Date | Chamber | Where | Type | Name | Committee Name |
---|---|---|---|---|---|
March 26, 2025 | Senate | Floor | Action | Introduction and first reading | |
March 26, 2025 | Senate | Floor | Action | Referred to | Health and Human Services |
Citations
[ { "analysis": { "added": [ "Clarifies requirements for photographic identification for buyers." ], "removed": [ "Previous packaging display requirements for business establishments." ], "summary": "This bill modifies restrictions placed on the sale of OTC allergy medicines under section 152.02 subdivision 6.", "modified": [ "Increases the amount of methamphetamine precursor drugs permissible per transaction." ] }, "citation": "152.02", "subdivision": "subdivision 6" }, { "analysis": { "added": [], "removed": [], "summary": "This provides an affirmative defense related to proof of age requirements for the sale of methamphetamine precursor drugs.", "modified": [ "Redefines conditions under which reliance on proof of age is considered reasonable." ] }, "citation": "340A.503", "subdivision": "subdivision 6" } ]